The Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, OR, USA.
Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
Methods Mol Biol. 2020;2142:73-80. doi: 10.1007/978-1-0716-0581-3_6.
Zika virus (ZIKV) is a newly emerged mosquito-borne flavivirus that has been associated with birth defects of babies born to ZIKV-infected mothers. Neutralization activity of serum derived from ZIKV infected and vaccinated individuals is a critical component for characterizing immune response to infection and vaccine efficacy. This protocol describes a modified plaque reduction neutralization 50 (PRNT50) assay that includes an immunostaining step to improve reproducibility and throughput of the assay.
Zika 病毒(ZIKV)是一种新出现的蚊媒黄病毒,与 ZIKV 感染母亲所生婴儿的出生缺陷有关。来自 ZIKV 感染和接种个体的血清的中和活性是表征对感染和疫苗效力的免疫反应的关键组成部分。本协议描述了一种改良的蚀斑减少中和 50(PRNT50)测定法,其中包括免疫染色步骤,以提高测定法的重现性和通量。